Matching articles for "Finlius"
Issue 1728 · May 12, 2025
Mirikizumab (Omvoh) — An IL-23 Antagonist for Crohn's Disease

The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in…

Med Lett Drugs Ther. 2025 May 12; 67(1728):78-80 doi:10.58347/tml.2025.1728d
The injectable interleukin (IL)-23 antagonist mirikizumab-mrkz ( Omvoh – Lilly) is now FDA-approved for treatment of moderately to severely active Crohn's disease (CD) in adults. Mirikizumab was approved in 2023 for treatment of ulcerative colitis. Two other IL-23 antagonists, risankizumab (Skyrizi) and guselkumab (Tremfya) , are also approved for treatment of CD.
Issue 1724 · March 17, 2025
Guselkumab (Tremfya) for Ulcerative Colitis

The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved…

Med Lett Drugs Ther. 2025 Mar 17; 67(1724):46-8 doi:10.58347/tml.2025.1724d
The interleukin (IL)-23 antagonist guselkumab ( Tremfya – Janssen Biotech) has now been approved by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was approved earlier for treatment of plaque psoriasis and psoriatic arthritis. Guselkumab is the third IL-23 antagonist to be approved in the US for treatment of UC; risankizumab (Skyrizi) and mirikizumab (Omvoh) were approved earlier.
Issue 1707 · July 22, 2024 Free
In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara

The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):119 doi:10.58347/tml.2024.1707e
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara (see Table 1). Wezlana is the first Stelara biosimilar to be approved in the US.